Navigation Links
Diatherix Laboratories Releases First Clinically Available Test For Confirmation of The Swine Flu Virus
Date:5/7/2009

Test can accurately confirm the H1N1 virus in six hours or less

HUNTSVILLE, Ala., May 7 /PRNewswire/ -- Diatherix Laboratories Inc. (www.diatherix.com) today released the first clinically available test that can definitively diagnose the current strain of H1N1 virus, also known as the swine flu, in six hours or less. The test is now commercially available to hospitals, private physician practices, and public health departments for the rapid confirmation of suspected H1N1 patients.

This test has been added to the company's viral respiratory panel, which uses proprietary molecular technology called Target Enriched Multiplex Polymerase Chain Reaction (Tem-PCR). Samples from confirmed patients, provided by the Centers for Disease Control and Prevention (CDC) and local hospitals, were used to validate the performance of the test. Until now, it took several days to confirm a suspected H1N1 patient due to the numerous rounds of testing needed to make a definitive diagnosis. Diatherix's advanced technology can identify multiple pathogens at one time, allowing them to detect and differentiate between the current strains of the H1N1 virus and other respiratory infections in one fast, accurate test.

"Due to the highly mutative nature of the H1N1 strains, it can be very difficult to diagnose the H1N1 virus with many of the current testing methods," said Jian Han, M.D., PhD, laboratory director at Diatherix and faculty investigator of the HudsonAlpha Institute for Biotechnology. "Because our Tem-PCR technology can test for multiple genetic targets at one time, it is the only rapid molecular test that, from a nasal swab, can detect and differentiate multiple influenza strains and nine other respiratory viruses in a single test. This advanced technology provides physicians an accurate and definitive diagnosis."

Dr. Han was responsible for the development of the Tem-PCR avian flu test for the Asian strain of H5N1 as well as a respiratory infection differentiation test used during the SARS outbreak in China. These tests played a significant role in preventing the spread of SARS and avian flu in Asia.

"Since the Diatherix test allows physicians to quickly differentiate H1N1 patients from those who have similar symptoms, infected patients can be provided proper antiviral therapy in a timely manner," said Dennis Grimaud, chief executive officer of Diatherix Laboratories. "A rapid confirmation of H1N1 patients can mitigate many of the negative economic and social impacts associated with infectious disease outbreaks. For example, if in 24 hours or less we could verify a suspected student was not infected with the H1N1 virus, this could prevent a school district from closing."

For information on using the Diatherix Tem-PCR test for the H1N1 virus, please visit the company's web site at www.diatherix.com or call (866) 656-1179.

Diatherix Laboratories Inc. is located in the Hudson-Alpha Institute for Biotechnology in Huntsville, Ala. Diatherix operates as an independent CLIA-certified clinical laboratory providing advanced multiplex molecular diagnostic services such as Tem-PCR to identify infectious disease to hospitals and the healthcare community. In addition to the H1N1 test, the company has testing panels for other respiratory infections, healthcare-associated infections and Staphylococcus. Diagnostic Network Alliance (DNA), with representative offices throughout the United States, is the exclusive US distributor for Diatherix Laboratory. DNA and Diatherix Laboratories share corporate administrative headquarters in Brentwood, Tenn.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Dennis Grimaud

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=86216


'/>"/>
SOURCE Diatherix Laboratories Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Vivek Y. Reddy, M.D., Joins The Mount Sinai Medical Center as Director of Electrophysiology Laboratories
2. Public Health Laboratories To Assume Primary Responsibility for Confirmatory Testing of Swine Flu
3. College of American Pathologists Is Confident in U.S. Laboratories Ability to Respond to Influenza Outbreak
4. Healthy Life Laboratories Announces Hemoglobin A1c iPhone Application
5. IDEXX Laboratories Announces First Quarter Results
6. Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorneys Office Investigation
7. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
8. Getting Closer to Controlling Cancer Requires Funding More Laboratories and Commitment Beyond Two Years of New Stimulus, Weiner and Berg Assert in Denver Post Oped
9. BioReference Laboratories Partners With Sysmex America
10. IDEXX Laboratories to Release 2009 First Quarter Financial Results
11. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... ... Brand EXOUS Bodygear announced today a special sale price for the EX-701 Knee ... the price will be only $19.97. The EXOUS Bodygear 65cm exercise ball ... $19.97). , The special promotional prices are to help individuals get their products at ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based ... into the challenges employers face in trying to balance both short-term and long-term ... programs? Adding to the growing complexity, companies are finding that the short-term ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... buildings (MOBs) and other outpatient facilities, and who are the most active developers? ... those questions, Revista and Healthcare Real Estate Insights (HREI) found that outpatient medical ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an ... 20, 2017, at 1:00 PM ET. A recording of the webinar will also be ... Series. , Home health and hospice companies are still popular targets for healthcare investors. ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... now have easier access to the robotic-assisted total-hip and partial-knee replacement surgeries ... Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently started performing these ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017  The leader in accelerated orthodontics, OrthoAccel ® ... Daher , Manal Ibrahim , Kenji Ojima ... be the featured microlecture presenters at the AcceleDent ® ... Orthodontists (AAO) Annual Session, April 21-25, 2017. Orthodontists and ... daily at 11:20 a.m. On the opening morning of ...
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, ... for GSP 301, an investigational fixed-dose combination of ... mcg) administered twice-daily as a nasal spray being ... These results are from a recently completed Phase ... GSP 301 combination therapy versus mometasone, olopatadine or ...
(Date:3/29/2017)... 29, 2017 Transparency Market ... provides an exhaustive study of the U.S. substance abuse ... companies are functional in this market at present, ... leading companies, such as GlaxoSmithKline Plc., Pfizer Inc., ... on various marketing strategies to increase their visibility, ...
Breaking Medicine Technology: